CompletedPhase 2NCT00283387
Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria
Studying Primary hyperoxaluria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Carla G Monico, M.D., M.DMayo Clinic Hyperoxaluria Center, Rochester MN
- Intervention
- Betaine(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 6-70 years · All sexes
- Timeline
- 2007 – 2011
Study locations (1)
- Mayo Clinic Hyperoxaluria Center, Rochester, Minnesota, United States
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Orphan Europe
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00283387 on ClinicalTrials.govOther trials for Primary hyperoxaluria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06839235Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)Arbor Biotechnologies
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06892301Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)Guangzhou Women and Children's Medical Center
- RECRUITINGEARLY PHASE1NCT06511349Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)RenJi Hospital
- RECRUITINGNCT06225882Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.Hospices Civils de Lyon
- ACTIVE NOT RECRUITINGNCT04982393BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)Alnylam Pharmaceuticals
- RECRUITINGPHASE2NCT04580420Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDDicerna Pharmaceuticals, Inc., a Novo Nordisk company